Literature DB >> 1489185

Penetration of zidovudine and 3'-fluoro-3'-deoxythymidine into the brain, muscle tissue, and veins in cynomolgus monkeys: relation to antiviral action.

E Ljungdahl-Ståhle1, E Guzenda, D Böttiger, B Wahren, B Oberg, L Ståhle.   

Abstract

Cynomolgus monkeys had microdialysis probes implanted under ketamine anesthesia into peripheral veins, thigh muscles, and the brain in order to sample the extracellular fluid for the concentrations of unbound nucleoside analogs. A dose of 25 mg of zidovudine or 3'-fluoro-3'-deoxythymidine (FLT) per kg was administered subcutaneously to each of three animals. Relatively high antiviral concentrations of FLT and zidovudine were present in peripheral tissues and in the brain. It was found that the concentration of zidovudine in the brain was approximately one-third of that in muscle and veins; the same relation was observed for FLT. The in vivo unbound concentrations of both drugs in the brain, muscle, and venous blood exceeded those reported to inhibit human immunodeficiency virus replication in vitro. In addition, in a correlative study we found that the appearance of p24 antigen in sera of monkeys infected with simian immunodeficiency virus was significantly delayed by both compounds (15 mg/kg three times daily for 9 days after infection). Thus, we have shown that the extracellular concentrations of unbound FLT and zidovudine in the brain and peripheral tissues attained with in vivo antiviral doses exceed in vitro antiviral concentrations.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1489185      PMCID: PMC284346          DOI: 10.1128/AAC.36.11.2418

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Pharmacokinetic estimations from microdialysis data.

Authors:  L Ståhle
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Antiviral effects of 3'-fluorothymidine and 3'-azidothymidine in cynomolgus monkeys infected with simian immunodeficiency virus.

Authors:  B Lundgren; D Böttiger; E Ljungdahl-Ståhle; E Norrby; L Ståhle; B Wahren; B Oberg
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1991

Review 3.  Targets and strategies for the antiviral chemotherapy of AIDS.

Authors:  E De Clercq
Journal:  Trends Pharmacol Sci       Date:  1990-05       Impact factor: 14.819

4.  An analysis of the inhibition of replication of HIV and MuLV by some 3'-blocked pyrimidine analogs.

Authors:  H Bazin; J Chattopadhyaya; R Datema; A C Ericson; G Gilljam; N G Johansson; J Hansen; R Koshida; K Moelling; B Oberg
Journal:  Biochem Pharmacol       Date:  1989-01-01       Impact factor: 5.858

5.  Brain and cerebrospinal fluid uptake of zidovudine (AZT) in rats after intravenous injection.

Authors:  R E Galinsky; B L Hoesterey; B D Anderson
Journal:  Life Sci       Date:  1990       Impact factor: 5.037

Review 6.  Molecular targets for AIDS therapy.

Authors:  H Mitsuya; R Yarchoan; S Broder
Journal:  Science       Date:  1990-09-28       Impact factor: 47.728

7.  Structure-activity relationships of fluorinated nucleoside analogs and their synergistic effect in combination with phosphonoformate against human immunodeficiency virus type 1.

Authors:  R Koshida; S Cox; J Harmenberg; G Gilljam; B Wahren
Journal:  Antimicrob Agents Chemother       Date:  1989-12       Impact factor: 5.191

8.  Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases.

Authors:  R W Klecker; J M Collins; R Yarchoan; R Thomas; J F Jenkins; S Broder; C E Myers
Journal:  Clin Pharmacol Ther       Date:  1987-04       Impact factor: 6.875

9.  3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.

Authors:  H Mitsuya; K J Weinhold; P A Furman; M H St Clair; S N Lehrman; R C Gallo; D Bolognesi; D W Barry; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

10.  Experimental infection of cynomolgus monkeys (Macaca fascicularis) with HIV-2.

Authors:  P Putkonen; B Böttiger; K Warstedt; R Thorstensson; J Albert; G Biberfeld
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1989
View more
  10 in total

Review 1.  Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue.

Authors:  Markus Müller; Amparo dela Peña; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

2.  Overview of microdialysis.

Authors:  T S Shippenberg; A C Thompson
Journal:  Curr Protoc Neurosci       Date:  2001-05

3.  Drug equilibration across the blood-brain barrier--pharmacokinetic considerations based on the microdialysis method.

Authors:  M Hammarlund-Udenaes; L K Paalzow; E C de Lange
Journal:  Pharm Res       Date:  1997-02       Impact factor: 4.200

Review 4.  Application of microdialysis in pharmacokinetic studies.

Authors:  W F Elmquist; R J Sawchuk
Journal:  Pharm Res       Date:  1997-03       Impact factor: 4.200

Review 5.  Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).

Authors:  E Sandström; B Oberg
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

6.  Microdialysis in pharmacokinetics.

Authors:  L Ståhle
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Jan-Mar       Impact factor: 2.441

Review 7.  Antiretroviral bioanalysis methods of tissues and body biofluids.

Authors:  Robin DiFrancesco; Getrude Maduke; Rutva Patel; Charlene R Taylor; Gene D Morse
Journal:  Bioanalysis       Date:  2013-02       Impact factor: 2.681

8.  Overview of brain microdialysis.

Authors:  Vladimir I Chefer; Alexis C Thompson; Agustin Zapata; Toni S Shippenberg
Journal:  Curr Protoc Neurosci       Date:  2009-04

9.  3'-Deoxy-3'-[(18)F]fluorothymidine and O-(2-[(18)F]fluoroethyl)-L-tyrosine PET in Patients with Suspicious Recurrence of Glioma after Multimodal Treatment: Initial Results of a Retrospective Comparative Study.

Authors:  Su Young Jeong; Tae Hyun Lee; Chang Hun Rhee; A Ra Cho; Byeong Il Kim; Gi Jeong Cheon; Chang Woon Choi; Sang Moo Lim
Journal:  Nucl Med Mol Imaging       Date:  2010-03-04

10.  Residual viremia in an RT-SHIV rhesus macaque HAART model marked by the presence of a predominant plasma clone and a lack of viral evolution.

Authors:  Robert C Kauffman; Andradi Villalobos; Joanne H Bowen; Lourdes Adamson; Raymond F Schinazi
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.